Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease

Haemophilia

Volumn 4, Issue SUPPL. 3, 1998, Pages 53-62

  Schwarz, H P ^a,b   Dorner, F ^a   Mitterer, A ^a   Mundt, W ^a   Schlokat, U ^a   Pichler, L ^a   Turecek, P L ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Animal model; Dog; Factor VIII; Recombinant; von Willebrand disease; von Willebrand factor

Indexed keywords

RISTOCETIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BLEEDING TIME; BLOOD FLOW; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DRUG HALF LIFE; EPISTAXIS; NONHUMAN; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0031773568     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.0040s3053.x     Document Type: Conference Paper

References (35)

1. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
2. Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-84.
3. Sadler JE, Davie EW. Hemophilia A, hemophilia B, and von Willebrand disease. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H (eds): The Molecular Basis of Blood Diseases, 2nd edn. Philadelphia, PA, Saunders & Co., 1995, pp. 657-700.
4. Montgomery RR, Coller BS. Von Willebrand disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia, PA, J.C. Lippincott, 1994, pp. 134-68.
5. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977; 60: 390-404.
6. Koppelman SJ, van Hoeij M, Lankhof H et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87: 2292-300.
7. Ruggeri ZM, Ware J. Von Willebrand factor. FASEB J 1993; 7: 308.
8. Federici AB. Diagnosis of von Willebrand disease. Haemophilia 1998; 4: 654-60.
9. Vlot A, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456-65.
10. Rosenberg JB, Foster PA, Kaufman RJ et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998; 101: 613-24.
11. Stokol T, Parry BW, Mansell PD. Factor VIII activity in canine von Willebrand disease. Veterinary Clinical Pathology 1995; 24:81-90.
12. Bouma BN, Dodds WJ, van Mourik JA, Sixma JJ, Webster WP. Infusion of human and canine factor VIII in dogs with von Willebrand's disease: Studies of the von Willebrand and factor VIII synthesis stimulating factors. Scand J Haematol 1976; 17: 263-75.
13. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilie and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-6.
14. Kraus KH, Johnson GS. Von Willebrand's disease in dogs. Current Veterinary Therapy 1989; 10:446-51.
15. Fischer BE, Schlokat U, Mitterer A, Reiter M et al. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin. FEBS Lett 1995; 375:259-62.
16. Schlokat U, Fischer B, Mitterer A et al. Herstellung und Charakterisierung von rekombinantem Willebrand-Faktor, in Scharrer I, Schramm W (eds): 26. Hämophilie-Symposion Hamburg 1995, Berlin, Springer Verlag, 1997, pp. 147-58.
17. Turecek PL, Gritsch H, Pichler L et al. In vivo characterisation of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997; 90: 3555-67.
18. Rieger M, Schwarz HP, Turecek PL, Dorner F, van Mourik JA, Mannhalter C. Identification of mutations in the canine von Willebrand factor gene associated with type III von Willebrand disease. Thromb Haemost 1998; 80: 332-7.
19. Macfarlane DE, Stibbe J, Kirby EP, Zucker M, Grant RA, McPherson J. A method for assaying von Willebrand factor (Ristocetin Cofactor). Thromb Diathes haemorrb 1975; 34: 306-8.
20. Evans RM, Austen DEG. Assay of ristocetin co-factor using fixed platelets and a platelet counting technique. Br J Haematol 1977; 37: 289-94.
21. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57:1140-3.
22. Aihara M, Sawada Y, Ueno K et al. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex. Thromb Haemost 1986; 55:263-7.
23. Austen DEG, Rhymes IL. A Laboratory Manual of Blood Coagulation, Oxford, Blackwell Scientific Publications, 1975
24. Lang H, Oberreither M, Moritz B. A new chromogenic factor VIII: C-assay based on a system of human proteins. Thromb Haemost 1991; 65: 943 (abstr).
25. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-730.
26. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of anibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997; 77: 591-9.
27. Lee ML, Popovsky MA, Kingdon HS. A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115: 745-8.
28. Cameron C, Notley C, Hoyle S et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998; 79: 317-22.
29. Roussi J, Turecek PL, André P et al. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease. Blood Coagul Fibrinolysis 1998; 9: 361-72.
30. Fischer BE, Turecek PL, Mitterer A et al. Multimeric composition and structural analysis of a recombinant von Willebrand factor (rvWF). Thromb Haemost 1995; 73: 1166 (abstr).
31. Furlan M, Robles R, Affolter D, Meyer D, Baillod P. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7.
32. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4.
33. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
34. Turecek PL, Furlan M, Lämmle B et al. Cleavage of recombinant von Willebrand factor (vWF) by a vWF-depolymerizing protease. Blood 1996; 88: 326a (abstr).
35. Schwarz HP, Turecek PL, Pichler L et al. Recombinant von Willebrand factor. Thromb Haemost 1997; 78: 571-76.